ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedside
10.1186/1756-8722-2-33
Saved in:
Main Authors: | Zhou, J., Chen, C.-S., Goh, B.-C., Albert, D.H. |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
2011
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/27024 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
by: Jasinghe, V.J., et al.
Published: (2011) -
In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor
by: Zhou, J., et al.
Published: (2011) -
In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor
by: Zhou, J., et al.
Published: (2011) -
In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor
by: Zhou, J., et al.
Published: (2011) -
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma
by: Toh, H.C., et al.
Published: (2014)